CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-26 | Kling Douglas F Chief Operating Officer | Option exercise · Restricted Stock Unit | −16,539 | 0 | ||
| 2025-03-26 | Davidson Michael H. Chief Executive Officer | Grant or award | +30,992 | 364,305 | ||
| 2025-03-26 | Davidson Michael H. Chief Executive Officer | Option exercise | +38,394 | 402,699 | ||
| 2025-03-26 | Davidson Michael H. Chief Executive Officer | Sale | −12,258 | 390,441 | ||
| 2025-03-26 | Davidson Michael H. Chief Executive Officer | Grant or award · Restricted Stock Unit | +38,394 | 38,394 | ||
| 2025-03-26 | Davidson Michael H. Chief Executive Officer | Option exercise · Restricted Stock Unit | −38,394 | 0 | ||
| 2025-03-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise | +150,000 | 150,000 | ||
| 2025-03-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Option exercise · Option (right to buy) | −150,000 | 820,229 | ||
| 2025-03-17 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +88,112 | 132,112 | ||
| 2025-03-17 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +11,888 | $10.00 | $119K | 144,000 |
| 2025-03-17 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −100,000 | 44,000 | ||
| 2025-03-17 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −88,112 | 47,251 | ||
| 2025-03-17 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −11,888 | 650,930 | ||
| 2025-03-04 | Topper James N Director | Purchase | +4,005 | $21.02 | $84K | 3,012,434 |
| 2025-03-04 | Kooij Louise Frederika Chief Accounting Officer | Option exercise | +150,000 | 165,000 | ||
| 2025-03-04 | Kooij Louise Frederika Chief Accounting Officer | Sale | −150,000 | $20.37 | $3.1M | 15,000 |
| 2025-03-04 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) | −150,000 | 18,073 | ||
| 2025-02-19 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +9,218 | 53,218 | ||
| 2025-02-19 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −9,218 | 44,000 | ||
| 2025-02-19 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −9,218 | 126,145 |
Page 10 of 15 · 300 trades